Statement by the VDGH On the Draft Bill for a Law on the Modernization of Assistive Devices and the Reduction of Bureaucracy (HiB)

The VDGH welcomes the draft’s goal of streamlining the administrative process for providing medical devices and establishing legal certainty. In order to achieve this goal with regard to the provision of continuous glucose monitoring (CGM) systems, the association believes that revisions or additions are necessary in four areas.

The VDGH represents manufacturers of in vitro diagnostic devices in Germany and, in addition, manufacturers of CGM systems. CGM systems are not in vitro diagnostic medical devices, but rather medical devices as defined by Regulation (EU) 2017/745. Under social security law, they are classified as medical aids pursuant to Section 33 of Book V of the Social Code (SGB V) and are listed in Product Group 21 of the Medical Aids Directory. Unlike in many other product areas, manufacturers here predominantly provide care to insured individuals themselves as service providers based on contracts under Section 127 of SGB V. The VDGH’s member companies are therefore directly affected by the regulations governing contract law, billing, and copayments.

CGM also represents a typical form of long-term care. Insured individuals with diabetes mellitus receive sensors at short, regular intervals over many years. Every administrative requirement that applies per delivery or per prescription is multiplied in this area of care. The VDGH evaluates the proposed regulations against this standard.

In a nutshell: The Association of the Diagnostics Industry (VDGH)

As a trade association, the German Diagnostics Industry Association (VDGH) represents the interests of more than 100 companies operating in Germany with a total turnover of 6.8 billion euros in 2022. They manufacture examination systems and reagents for the diagnosis of human diseases, which generate a turnover of more than 3.5 billion euros, as well as instruments, reagents, test systems and consumables for research in the life sciences, which generate a turnover of 3.3 billion euros.

www.vdgh.de

Your press contact

Torsten Kiesner

Press and communication

+49 30 200 599-43